MAM
CRL icon

Mastrapasqua Asset Management’s Charles River Laboratories CRL Stock Holding History

Mastrapasqua Asset Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$2.48M Sell
12,654
-55
-0.4% -$11.3K 0.29% 67
2023
Q2 		$2.67M Sell
12,709
-12
-0.1% -$2.39K 0.3% 67
2023
Q1 		$2.57M Sell
12,721
-916
-7% -$208K 0.32% 67
2022
Q4 		$2.97M Sell
13,637
-197
-1% -$43K 0.39% 64
2022
Q3 		$2.72M Buy
13,834
+201
+1% +$43.4K 0.39% 68
2022
Q2 		$2.92M Sell
13,633
-709
-5% -$173K 0.4% 69
2022
Q1 		$4.07M Sell
14,342
-742
-5% -$229K 0.46% 63
2021
Q4 		$5.68M Sell
15,084
-497
-3% -$193K 0.56% 55
2021
Q3 		$6.43M Sell
15,581
-215
-1% -$89.3K 0.7% 48
2021
Q2 		$5.84M Buy
15,796
+422
+3% +$141K 0.62% 53
2021
Q1 		$4.46M Buy
15,374
+2,661
+21% +$740K 0.52% 59
2020
Q4 		$3.18M Sell
12,713
-727
-5% -$173K 0.42% 64
2020
Q3 		$3.04M Sell
13,440
-134
-1% -$27.8K 0.43% 64
2020
Q2 		$2.37M Buy
13,574
+49
+0.4% +$7.82K 0.36% 68
2020
Q1 		$1.71M Sell
13,525
-175
-1% -$26.2K 0.33% 65
2019
Q4 		$2.09M Buy
13,700
+180
+1% +$24.9K 0.34% 75
2019
Q3 		$1.79M Buy
13,520
+85
+0.6% +$11.4K 0.33% 74
2019
Q2 		$1.91M Buy
13,435
+10
+0.1% +$1.36K 0.36% 74
2019
Q1 		$1.95M Sell
13,425
-10
-0.1% -$1.31K 0.37% 76
2018
Q4 		$1.52M Buy
13,435
+255
+2% +$31.9K 0.34% 75
2018
Q3 		$1.77M Sell
13,180
-160
-1% -$19.7K 0.34% 74
2018
Q2 		$1.5M Buy
13,340
+4,440
+50% +$480K 0.3% 82
2018
Q1 		$950K Buy
8,900
+835
+10% +$90K 0.19% 98
2017
Q4 		$883K Sell
8,065
-550
-6% -$59.9K 0.18% 100
2017
Q3 		$931K Buy
+8,615
New +$885K 0.19% 95

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Mastrapasqua Asset Management's CRL Position: Q3 2023 in Review

Mastrapasqua Asset Management reduced its Charles River Laboratories (CRL) stake by 0.43% in Q3 2023, selling an estimated $11.3K and leaving 12,654 shares worth $2.48M. The position accounts for 0.29% of the portfolio, ranked #67.

Mastrapasqua Asset Management first reported a position in CRL in Q3 2017 and has held it in 25 quarters since. The position peaked at $6.43M in Q3 2021. 621 funds tracked by Wall St. Rank hold CRL as of Q3 2023.

  • Mastrapasqua Asset Management held 12,654 shares of Charles River Laboratories worth $2.48M as of Q3 2023.
  • Mastrapasqua Asset Management sold 55 Charles River Laboratories shares in Q3 2023, an estimated $11.3K.
  • Charles River Laboratories made up 0.29% of Mastrapasqua Asset Management's portfolio in Q3 2023, its #67 holding.
  • Mastrapasqua Asset Management first reported a position in Charles River Laboratories in Q3 2017 and has held it in 25 quarters since.
  • Mastrapasqua Asset Management's Charles River Laboratories position peaked at $6.43M in Q3 2021.
  • 621 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.

Based on Mastrapasqua Asset Management's 13F filing for Q3 2023, filed 25 Oct 2023.